Esperion Therapeutics ESPR Net deferred tax assets, before valuation allowance
Net deferred tax assets, before valuation allowance at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's net deferred tax assets, before valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's net deferred tax assets, before valuation allowance?
- Esperion Therapeutics (ESPR) reported net deferred tax assets, before valuation allowance of $417.1M in Q4 2025.
- How has Esperion Therapeutics's net deferred tax assets, before valuation allowance changed year-over-year?
- Esperion Therapeutics's net deferred tax assets, before valuation allowance increased by 1.0% year-over-year, from $413.1M to $417.1M.
- What is the long-term trend for Esperion Therapeutics's net deferred tax assets, before valuation allowance?
- Over 5 years (2020 to 2025), Esperion Therapeutics's net deferred tax assets, before valuation allowance has grown at a 15.5% compound annual growth rate (CAGR), from $202.8M to $417.1M.
- What does net deferred tax assets, before valuation allowance mean?
- This represents the gross value of deferred tax assets before the application of a valuation allowance. It reflects the potential future tax benefits arising from temporary differences between the financial reporting and tax bases of assets and liabilities. Investors monitor this to assess the company's potential to reduce future tax liabilities through existing tax attributes.